Thesis Timeline
When each thesis is expected to play out — derived from forward revenue guidance and margin trend, not from price action. A thesis has ramped when its demand shows up in reported numbers.
Ramp map
18 thesesPermanent Magnets: Rare Earth Supply Squeeze
Rare Earth Minerals · 72%
Peptide Therapeutics and Consumer Longevity Bull Case
Peptide Therapeutics · 62%
Semiconductor Supply Chain Inheritance Advantage
Agentic AI - Next Computing Platform
Rare Earth Supply-Demand Reckoning
Peptide Therapeutics and Consumer Longevity Bull Case
Peptide Therapeutics · 62%
Nuclear Renaissance Powering AI Data Centers
NVIDIA 800V DC Architecture: Powering the AI Factory Era
NVIDIA 800V DC Architecture: Powering the AI Factory Era · 78%
The Swarm Drone Age: Autonomous Warfare & Commercial Drones
The Swarm Drone Age: Autonomous Warfare & Commercial Drones · 78%
HALEU Fueling Advanced Nuclear Renaissance
Nuclear Energy · 42%
Rotation From AI Into Quality Insurance
Insurance Value Rotation · 72%
SpaceX Wireless Buildout Boosts Tower & Fiber Enablers
Solar Dominance: Economics-Driven Multi-Year Expansion
Solar Energy · 55%
Enrichment Chokepoint of Nuclear Renaissance
Nuclear Energy · 55%
Uranium Enrichment Bottleneck: SWU Squeeze
Nuclear Fuel Cycle · 40%
AI Drug Discovery Picks and Shovels
AI Healthcare · 55%
HALEU Fuel Supply Chain Investment Thesis
Nuclear Energy · 45%
Europe PFAS Remediation Capex Supercycle
PFAS Remediation · 55%
Thesis already ramping: MP revenue +89% YoY and NOPMF +79.4% with expanding margins; consensus sees acceleration into 2026-Q4/2027-Q1.
Thesis already inflects in 2026-Q4 via LLY (rev +28.5% next Q, op margin +909 bps) and GLP API demand (+57.9% next Q), despite NVO contraction.
Already playing out: TSM, ASML, LRCX, AMAT, NVDA all show accelerating revenue and expanding margins in reported 2026-Q2/Q3 numbers.
Thesis is already playing out: NVDA, PLTR, and AMD show triple-digit or accelerating revenue with expanding margins now; agentic adoption phase hits 2026-Q4 through 2027-Q2.
Demand is already visible: MP +122% and UUUU +113% next-quarter consensus, with NOPMF margins expanding, so the thesis shows up in reported numbers starting 2026-Q4 earnings.
Thesis inflects by 2027-Q1 as GLP's 58-70% projected sales growth and LLY's margin expansion show up in reported numbers.
Thesis already visible: TLN, CEG, VST report 39-67% consensus sales growth in 2026-Q4 with TLN margins expanding ~2000bps; SMR/OKLO remain story stocks.
Thesis inflects in 2027-Q1 as Vera Rubin/Kyber 800V ramps hit baskets: NVTS +107% Q+2, IFX.DE +27.5%, GEV +27.4%.
Thesis is already visible: KTOS revenue +30.5% and RCAT +527% reported, with AVAV reaccelerating to ~30% in Q+2.
Thesis plays out in 2027 at earliest: near-term consensus sales are flat or negative across the basket; growth is concentrated in FY-next estimates.
Stalled: consensus shows low single-digit revenue growth and negative FY-next EPS across most of the basket, with no margin expansion visible.
No SpaceX-driven ramp visible: consensus shows flat or negative revenue across five of six names with contracting margins; earliest inflection not before late 2027.
Thesis inflects in FY2027 (2027-Q3), when FSLR's +18% next-FY sales and NXT's +20.2% show up; near-term consensus is mostly negative.
Enrichment demand is not yet in reported numbers; HALEU-driven revenue and margin inflection likely shows in 2027-H2 through 2028.
Core enricher Centrus shows contracting sales and margins, so the SWU squeeze thesis won't show in reported numbers before late 2027.
Compute layer (NVDA +91% next Q) is ramping now, but AI-drug-discovery enablers (RXRX, SDGR) show declining revenue, pushing thesis confirmation to 2027-Q3 at earliest.
HALEU demand hits reported numbers late 2027: BWXT grows steadily now, LEU margin recovery after 2027 HALEU ramp, SMR/OKLO revenue inflects 2028.
Compliance demand is not yet in consensus numbers; PFAS capex inflection unlikely before 2028-Q1 at earliest.